Literature DB >> 19837238

Possible harms of oseltamivir--a call for urgent action.

Tom Jefferson1, Mark Jones, Peter Doshi, Chris Del Mar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19837238     DOI： 10.1016/S0140-6736(09)61804-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  Antivirals for influenza: strategies for use in pediatrics.

Authors:  Steven M Smith; John G Gums
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

2.  Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance.

Authors:  Takuro Okada; Masayuki Hashiguchi; Satoko Hori
Journal:  Int J Clin Pharm       Date:  2022-09-26

Review 3.  Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.

Authors:  Tom Jefferson; Mark Jones; Peter Doshi; Chris Del Mar
Journal:  BMJ       Date:  2009-12-08

4.  Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.

Authors:  Michael M Kaminski; Annette Ohnemus; Peter Staeheli; Dennis Rubbenstroth
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

5.  During the summer 2009 outbreak of "swine flu" in Scotland what respiratory pathogens were diagnosed as H1N1/2009?

Authors:  Rory N Gunson; William F Carman
Journal:  BMC Infect Dis       Date:  2011-07-13       Impact factor: 3.090

6.  Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database.

Authors:  Hisashi Urushihara; Yuko Doi; Masaru Arai; Toshiyuki Matsunaga; Yosuke Fujii; Naoko Iino; Takashi Kawamura; Koji Kawakami
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

7.  Health costs from hospitalization with H1N1 infection during the 2009-2010 influenza pandemic compared with non-H1N1 respiratory infections.

Authors:  Paul Zarogoulidis; Dimitrios Glaros; Theodoros Kontakiotis; Marios Froudarakis; Ioannis Kioumis; Ioannis Kouroumichakis; Anastasios Tsiotsios; Anastasios Kallianos; Paschalis Steiropoulos; Konstantinos Porpodis; Evagelia Nena; Despoina Papakosta; Aggeliki Rapti; Theodoros C Constantinidis; Theodora Kerenidi; Maria Panopoulou; Georgia Trakada; Nikolaos Courcoutsakis; Evangelia Fouka; Konstantinos Zarogoulidis; Efstratios Maltezos
Journal:  Int J Gen Med       Date:  2012-03-05

8.  Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.

Authors:  Annicka Reuss; Manuel Dehnert; Silke Buda; Walter Haas
Journal:  Influenza Other Respir Viruses       Date:  2013-08-20       Impact factor: 4.380

Review 9.  Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials.

Authors:  Alex Hodkinson; Carrol Gamble; Catrin Tudur Smith
Journal:  Trials       Date:  2016-04-22       Impact factor: 2.279

10.  Clinical differences between influenza A (H1N1) virus and respiratory infection between the two waves in 2009 and 2010.

Authors:  Paul Zarogoulidis; Dimitrios Glaros; Ioannis Kioumis; Eirini Terzi; Konstantinos Porpodis; Anastasios Tsiotsios; Anastasios Kallianos; Georgia Trakada; Nikolaos Machairiotis; Aikaterini Stylianaki; Antonis Sakas; Ageliki Rapti; Nikolaos Courcoutsakis; Theodoros C Constantinidis; Efstartios Maltezos; Konstantinos Zarogoulidis
Journal:  Int J Gen Med       Date:  2012-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.